Space infrastructure company Redwire Corporation (NYSE: RDW) on Wednesday announced a collaboration with biopharmaceutical company Bristol Myers Squibb (BMS) to study small molecule drug compounds aboard the International Space Station (ISS).
Utilising Redwire's PIL-BOX pharmaceutical development platform, this mission aims to enhance drug stability, streamline manufacturing, and improve efficiencies across oncology, immunology, and cardiovascular therapies.
In addition, Redwire is launching another PIL-BOX investigation with ExesaLibero Pharma, targeting ELP-004, a drug that addresses excess bone removal linked to conditions like rheumatoid arthritis, multiple myeloma and certain cancers. This mission will support the development of advanced treatments for bone diseases.
A third experiment, conducted with Butler University, seeks to produce high-quality seed crystals in microgravity, potentially advancing pharmaceutical production on Earth. This is Butler's second investigation using PIL-BOX.
Redwire has launched 16 PIL-BOX missions to date, with 12 more scheduled aboard the upcoming SpaceX-31 cargo resupply flight to the ISS. The company aims to drive breakthroughs in drug development and other advanced technologies with significant commercial potential through its space-based research initiatives.
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD